A Phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC)

References

• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, . Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27: 3584–90.
   PubMed Web of Science ®Google Scholar
• Johannsen M, Florcken A, Bex A, Roigas J, Cosentino M, Ficarra V, . Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol 2009;55:1430–8.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, . High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105–16.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G. High-dose aldesleukin in renal cell carcinoma: Long-term survival update. Cancer J Sci Am 1997;(Suppl 1): S70–2.
   Google Scholar
• Coquet JM, Kyparissoudis K, Pellicci DG, Besra G, Berzins SP, Smyth MJ, . IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 2007;178:2827–34.
   PubMed Web of Science ®Google Scholar
• Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, . Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000;408(6808):57–63.
   PubMedGoogle Scholar
• Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV. Interleukin 21: Combination strategies for cancer therapy. Nat Rev Drug Discov 2008;7:231–40.
   PubMed Web of Science ®Google Scholar
• Brady J, Hayakawa Y, Smyth MJ, Nutt SL. IL-21 induces the functional maturation of murine NK cells. J Immunol 2004; 172:2048–58.
   PubMed Web of Science ®Google Scholar
• Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, . Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 2005;201: 139–48.
   PubMed Web of Science ®Google Scholar
• Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A, . A critical role for IL-21 in regulating immunoglobulin production. Science 2002;298:1630–4.
   PubMed Web of Science ®Google Scholar
• Kuchen S, Robbins R, Sims GP, Sheng C, Phillips TM, Lipsky PE, . Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration. J Immunol 2007;179:5886–96.
   PubMed Web of Science ®Google Scholar
• Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, . IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007;8:967–74.
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, . IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007;448:484–7.
   PubMed Web of Science ®Google Scholar
• Peluso I, Fantini MC, Fina D, Caruso R, Boirivant M, MacDonald TT, . IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 2007;178:732–9.
   PubMed Web of Science ®Google Scholar
• McDermott DF. Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin Cancer Res 2007;13:716s–20s.
   PubMed Web of Science ®Google Scholar
• Foster D, Parrish-Novak J, Fox B, Xu W. Cytokine-receptor pairing: accelerating discovery of cytokine function. Nat Rev Drug Discov 2004;3:160–70.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hudes G, Wilding G, Schwartz LH, Hariharan S, Kempin S, . Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009;7:28–33.
   PubMed Web of Science ®Google Scholar
• Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, . Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007;13:1801–9.
   PubMed Web of Science ®Google Scholar
• Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, . Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007;25:3288–95.
   PubMed Web of Science ®Google Scholar
• Ryan CW, Goldman BH, Lara PN, Jr., Mack PC, Beer TM, Tangen CM, . Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: A phase II study of the Southwest Oncology Group. J Clin Oncol 2007;25: 3296–301.
   PubMed Web of Science ®Google Scholar
• Flaig T, Curti B, Gordon M, Van Veldhuizen P, Miller W, Ernstoff M. Recombinant IL-21 in combination with sorafenib as second- or third-line therapy for metastatic renal cell carcinoma (mRCC): Interim results from a phase 2 study [abstract]. Eur J Cancer Suppl 2008;204.
   Google Scholar
• Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, . Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008;111:5610–20.
   PubMed Web of Science ®Google Scholar
• Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, . The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009;69:2514–22.
   PubMed Web of Science ®Google Scholar
• Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, . Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148–57.
   PubMed Web of Science ®Google Scholar
• van CH, van d, V, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, . Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res 2008;14:5884–92.
   PubMedGoogle Scholar
• Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, . Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674–82.
   PubMed Web of Science ®Google Scholar
• Davis ID, Skak K, Smyth MJ, Kristjansen PE, Miller DM, Sivakumar PV. Interleukin-21 signaling: Functions in cancer and autoimmunity. Clin Cancer Res 2007;13:6926–32.
   PubMed Web of Science ®Google Scholar
• Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, . Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008;26:2034–9.
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, . Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:4068–75.
   PubMed Web of Science ®Google Scholar